- US Patent and Trademark Office has granted Exopharm patent US 11202805, for its LEAP™ exosome purification technology.
- LEAP™ enables large-scale, clinical grade commercial production of exosomes needed to underpin the emerging field of exosome medicines.
- Exopharm is seeking potential partners and licensees, with LEAP™ having the potential to become the industry standard for exosome production, as well as developing its own pipeline of exosome medicines.
22 December 2021, Melbourne, Australia: Exopharm Limited (ASX:EX1) has been granted US patent US 11202805 for its LEAP™ exosome purification technology. This patent positions Exopharm as a global leader in meeting the challenge of large-scale, commercial production of exosomes needed to enable leading-edge exosome medicines.
The latest research points to exosomes as a better and safer way to deliver modern medicines, including mRNA vaccines that currently use lipid nanoparticles.
“This patent is potentially a game-changer for Exopharm. Securing a US patent for an important biotechnology manufacturing technology is major milestone and adds value to our company. Our LEAP™ technology has the capability to become the industry standard for exosome medicines, a field that is growing strongly and is attracting big companies,” said Dr Ian Dixon, founder and CEO of Exopharm and a co-inventor on the LEAP™ patent.
“LEAP™ is one part of Exopharm’s intellectual property and know-how. We are in discussions with potential partners that can use LEAP™ to make and commercialise their own exosome medicines for a wide range of diseases including global contract manufacturing organisations like Showa Denko,” said Dr Chris Baldwin, Chief Commercial Officer and Deputy CEO of Exopharm.
“While partnering can deliver early revenue and help make exosome medicines mainstream, the long-term future for Exopharm is in developing our own modern exosome medicines,” said Dr Ian Dixon.
Exopharm’s product pipeline seeks to maximise the value of selected exosome medicines to solve real medical problems in rare disease and general health areas.
The LEAP™ patent has already been granted in Russia, and Exopharm continues to pursue this patent family in a further 10 key global jurisdictions.
Further information on LEAP™ is available on the Exopharm web site www.exopharm.com
This announcement has been authorised for release by the Managing Director.
Company and Media Enquiries:
Join our mailing list to receive updates:
P: +61 (0)3 9111 0026
Tel: +61 (0)3 9620 3333
Exopharm Limited (ASX:EX1) is a clinical-stage biopharmaceutical company at the forefront of transformative medicines using exosomes, or extracellular vesicles (EVs), and is pursuing a pipeline-driven platform strategy.
Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell and tissue types (tropism) – improving the safety profile of the APIs and providing better treatments.
Exosome delivery of DNA and other gene therapies into the nucleus of the patient’s cells can improve treatment of inherited medical conditions.
Exosomes are an alternative means of drug delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes. The drug delivery industry is growing at a compound annual growth rate (CAGR) of 5% and is currently valued at about US$175 billion ($233 billion).
Exopharm’s exosome technologies meet important needs for the success of exosome medicines – LEAP™ manufacturing technology, LOAD API loading and EVPS tropism.
Exopharm’s suite of exosome technologies enables its own pipeline of exosome medicines – each aimed at delivering a transformative medicine for an unmet medical need.
Exopharm’s intellectual property is also available under licences or partnerships to empower others to build their pipelines around the benefits of exosome medicines.
FORWARD LOOKING STATEMENTS
This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as ‘intends’, ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘aims’, ‘plans’ or ‘expects’. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm’s control or subject to the success of the Development Program. Furthermore, the Company is subject to several risks as disclosed in the Prospectus dated 6 November 2018.
 Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity by
Tsai et al 2021 https://doi.org/10.1016/j.jbc.2021.101266
 Pharma Formulations 2021 Track 12: Novel Drug Delivery Systems https://formulations.pharmaceuticalconferences.com/